Report cover image

Pneumococcal Infections Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20147015

Description

Pneumococcal infections are very common and affect a significant portion of the population. The incidence of invasive pneumococcal vaccines is higher in very young children, aged 2 years or under and in individuals aged 65 years or above. As a result, major companies are engaging in research and development activities to provide effective solutions to patients.

Report Coverage

The Pneumococcal Infections Drug Pipeline Report by Expert Market Research gives comprehensive insights into pneumococcal infection drugs currently undergoing pneumococcal infections clinical trials. It covers various aspects related to the details of each of these pneumococcal infections drugs under development for pneumococcal infections. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The pneumococcal infections pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from pneumococcal infections.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing pneumococcal infections product development activities are covered.  Moreover, pneumococcal infections collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.

Pneumococcal Infections Drug Pipeline Outlook

Pneumococcal infections are caused by Streptococcus pneumoniae bacteria and can be divided into 2 types. Non-invasive pneumococcal infections occur outside the major organs of the body and can be considered less serious. It includes diseases like sinusitis, bronchitis and otitis media. Whereas invasive pneumococcal infections affect a major organ or blood and are more serious. Bacteraemia, Septicaemia, Osteomyelitis, Pneumonia and Meningitis are examples of invasive pneumococcal infections.

Pneumococcal infections are diagnosed through blood tests, urine tests, phlegm tests and imaging tests. Most infections can be treated with the help of early diagnosis and antibiotics. However, antibiotic resistant indications may need another strong alternative. Pneumococcal vaccines are also advised to people for avoiding the risk of such infections.

Pneumococcal Infections – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of pneumococcal infections drug candidates based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class

EMR’s pneumococcal infections therapeutic assessment report covers 50+ drug analyses based on drug classes:
  • Beta-Lactam Antibiotics
  • Macrolides
  • Fluoroquinolones
  • Glycopeptides
  • Tetracyclines
  • Oxazolidinones
By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
  • Oral
  • Parenteral
  • Others
Pneumococcal Infections – Pipeline Assessment Segmentation, By Phases

The pneumococcal infections report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for pneumococcal infections. There are around 157 drugs in phase III of pneumococcal infection drugs.

Pneumococcal Infections – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under pneumococcal infections pipeline analysis include beta-lactam antibiotics, macrolides, fluoroquinolones, glycopeptides, tetracyclines, and oxazolidinones. Beta-lactam antibiotics include penicillins, aminopenicillins and cephalosporins. The choice of treatment depends on the site of infection, the patient's age, potential resistance patterns, and other underlying health symptoms.

Pneumococcal Infections Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR pneumococcal infections report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in pneumococcal infection clinical trials:
  • Merck Sharp & Dohme LLC
  • Pfizer
  • Sanofi
  • GlaxoSmithKline
  • ImmunoBiology Limited
  • Sinovac Life Sciences Co., Ltd.
  • Walvax Biotechnology Co., Ltd.
Pneumococcal Infections – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for pneumococcal infections. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of pneumococcal infections drug candidates.

V116

In April 2024, Merck announced positive results for their investigational adult-specific 21-valent pneumococcal conjugate vaccine, V116. It was under investigation in the STRIDE-10 clinical trial and demonstrated a comparable safety profile to its counterparts including PPSV23. Moreover, the FDA offered a priority review for the vaccine in June 2024.

PCV20

Researchers are evaluating PCV20 (a 20-valent pneumococcal conjugate vaccine) for its safety, immunogenicity and tolerability to treat pneumococcal disease in children. Currently in Phase 3, PCV20 is equipped with 13-valent PCV (PCV13) components and 7 additional polysaccharide conjugates for extended protection.

13vPnC

Sponsored by Pfizer, 13vPnC (13-Valent Pneumococcal Conjugate Vaccine) is in Phase 3 of an open-label single-arm, multicenter, trial to assess the safety, tolerability and immunogenicity in adults with pneumococcal infections and are aged 50 years or above.

Reasons To Buy This Report

The Pneumococcal Infections Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for pneumococcal infections. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within pneumococcal infections pipeline insights.

Key Questions Answered in the Pneumococcal Infections – Pipeline Insight Report
  • Which companies/institutions are leading the pneumococcal infections drug development?
  • What is the efficacy and safety profile of pneumococcal infections pipeline drugs?
  • Which company is leading the pneumococcal infections pipeline development activities?
  • What is the current pneumococcal infections commercial assessment?
  • What are the opportunities and challenges present in the pneumococcal infections drug pipeline landscape?
  • What is the efficacy and safety profile of pneumococcal infections pipeline drugs?
  • Which company is conducting major trials for pneumococcal infections drugs?
  • Which companies/institutions are involved in pneumococcal infections collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in pneumococcal infections?
Related Reports

Pneumococcal Vaccine Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Overview of Pneumococcal Infections
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Pneumococcal Infections: Epidemiology Snapshot
5.1 Pneumococcal Infections Incidence by Key Markets
5.2 Pneumococcal Infections– Patients Seeking Treatment in Key Markets
6 Pneumococcal Infections: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Pneumococcal Infections: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Pneumococcal Infections, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Pneumococcal Infections Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Pneumococcal Infections Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 13vPnC
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 V116
10.2.3 Investigational 23-valent PPV
10.2.4 Other Drugs
11 Pneumococcal Infections Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 VAX-31
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Other Drugs
12 Pneumococcal Infections Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 XJ103
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Pneumococcal Infections Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Drug 2
13.2.3 Other Drugs
14 Pneumococcal Infections, Key Drug Pipeline Companies
14.1 Merck Sharp & Dohme LLC
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Pfizer
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Sanofi
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 GlaxoSmithKline
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 ImmunoBiology Limited
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Sinovac Life Sciences Co., Ltd.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Walvax Biotechnology Co., Ltd.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 Novartis Vaccines
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us